CoChat

Cardiovascular and non‐cardiovascular safety of dipeptidyl peptidase‐4 inhibition: a meta‐analysis of randomized controlled cardiovascular outcome trials

Abbas, A. S., Dehbi, H.‐M., Ray, K. K. · 2016 · Diabetes, Obesity and Metabolism
Cited by 62

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Abstract

The full licensing of dipeptidyl peptidase‐4 ( DPP ‐4) inhibitors in the USA and E urope requires demonstration of cardiovascular ( CV ) safety with an upper boundary of harm of <30%. We report a total of 3334 CV events during 86 716 person‐years of follow‐up in 36 543 patients, when combining data from three trials with formal and prospectively assessed endpoints. Fixed‐effect meta‐analysis showed that, compared with placebo, DPP ‐4 inhibition did not increase the upper boundary of risk for the composite endpoint, nor for any individual component by >30%. Relative risks ( RRs ) were: 0.99 [confidence interval ( CI ) 0.93–1.06] for composite CV ‐specific death, non‐fatal myocardial infarction ( MI ) and non‐fatal stroke; 1.01 ( CI 0.91–1.12) for CV ‐specific death; 0.98 ( CI 0.89–1.09) for non‐fatal MI ; and 1.00 ( CI 0.86–1.16) for non‐fatal stroke. The risk of acute pancreatitis was increased ( RR 1.79; CI 1.13–2.81), equating to 5.5 extra cases/10 000 patients/year (weighted mean) and a number needed to harm of 1940/year. These data provide reassurance about the safety of DPP ‐4 inhibitors with regard to individual atherothrombotic events and a safety signal for pancreatitis.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/dom.12595

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 62

Metadata

Authors
Abbas, A. S., Dehbi, H. ‐., & Ray, K. K.
Venue
Diabetes, Obesity and Metabolism
Publisher
Wiley
Published
2015-12-23
Volume
18
Issue
3
Pages
295-299
ISSN
  • 1462-8902 (ISSN-L)
  • 1463-1326
OpenAlex
W1930603471
Cited by
62
References
5
FWCI
8.61
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.